The Effect of Exparel on Post Operative Pain and Narcotic Use After Colon Surgery

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the effect of Exparel on pain control and patient outcome after colon resection. The investigators will evaluate the clinical course of the patients who receive exparel as compared to the patients who do not receive exparel. Exparel is a 72 hour bupivacaine which is slowly released from lysosomes over the course of three days. A long acting local anesthetic should provide better pain control than conventional bupivacaine which has a 3.5 hour half-life.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Des Moines University
• Collaborator: Mercy Medical Center
• Treatments: Anesthetics; Anesthetics, Local; Bupivacaine; Narcotics

Criteria

Inclusion Criteria:

• Elective colon resection for both benign and malignant disease

• Laparoscopic, robotic and open techniques

Exclusion Criteria:

• emergent colon cases

• cases preformed by surgeons other than Dr. Raman or Dr. Kraemer

• pregnant patients

• patients currently breast feeding

• patients under the age of 18

• other patients unable to give informed consent

• bupivacaine use within 96 hours

• allergy to amide anesthetics

• prisoners

• caution will be used in patients with renal or hepatic failure.